Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference54 articles.
1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011
2. Fundamental mechanisms of immune checkpoint blockade therapy;Wei;Cancer Discov,2018
3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010
4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015
5. Immune-related adverse events associated with immune checkpoint blockade;Postow;N Engl J Med,2018
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy in melanoma: advances, pitfalls, and future perspectives;Frontiers in Molecular Biosciences;2024-06-28
2. Development of Personalized Strategies for Precisely Battling Malignant Melanoma;International Journal of Molecular Sciences;2024-05-04
3. Evaluation of colitis induced by immune-checkpoint inhibitors therapy in melanoma patients by an overall grading scale;Journal of Oncology Pharmacy Practice;2024-04-23
4. Long‐term follow‐up results from KEYNOTE‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma;The Journal of Dermatology;2024-03-26
5. Management of Locally Invasive and Metastatic Eyelid Tumours;Oculoplastic, Lacrimal and Orbital Surgery;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3